This web site is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

JNJ-42756493

Johnson & Johnson

Drug Names(s): JNJ42756493, JNJ-493

Description: JNJ-42756493 is a pan-fibroblast growth factor receptor (FGFR) tyrosine kinase inhibitor.

Deal Structure: Astex and Janssen
In June 2008, Astex and Janssen entered into a research alliance focused on the research, development and commercialisation of novel drugs for the treatment of cancer. The new agreement grants Janssen a worldwide exclusive license to compounds arising from Astexs novel FGFR inhibitor program, and the parties are also to establish a new drug discovery alliance focused on the identification of novel inhibitors against a further two cancer drug targets. Under the terms of the agreement, Ortho Biotech Research & Development, the research and development arm of Janssen, will be responsible for completing all of the pre-clinical and clinical development of all products arising from the collaboration and for their commercialisation globally. The agreement also grants Astex an option to co-commercialise FGFR products developed under the collaboration in the USA.

Astex and Otsuka
In September 2013, Otsuka and Astex announced that their respective...See full deal structure in Biomedtracker

Partners: Otsuka Holdings Co., Ltd.


JNJ-42756493 News


Additional information available to subscribers only:

  • Targets
  • Routes
  • Catalysts
  • Designations
  • Events

Request a Free Demo Subscriber Login Search for another drug